Blog Category Archive

Life Sciences

VIEW ALL BLOG POSTS

26 Apr
2017

Posted by
Shauna Leighton

Compliance is Key: 4 Life Sciences Verticals that Need Sales Enablement

Biotechnology. Diagnostics. Medical Devices. Pharmaceuticals. What do these four life sciences verticals have in common? The need for compliant content. In such a highly-regulated industry, life sciences companies are under pressure to reduce operational costs and increase efficiency, all while improving patient outcomes. They’re responsible for making sure that their drugs, devices, or tests are safe and…

CONTINUE

19 Apr
2017

Posted by
Shauna Leighton

3 Ways Sales Enablement is Shaking Up Life Sciences

While life science companies are some of the most innovative organizations, it’s been said that the healthcare industry is typically five years behind technology trends. Although it’s usually the end user or regulatory requirements that hamper adoption and onboarding, it doesn’t mean that Marketing and Sales need to suffer from a lack of technological advancements…

CONTINUE

12 Apr
2017

Posted by
Shauna Leighton

The Power of Personalized Content for a Personalized Medical Movement

As a marketer, ensuring that the right message is delivered to the right person at the right time can be challenging. Perhaps a company’s buyer personas are mapped out, everyone understands each stage of the buyer’s journey, and all content efforts are streamlined, but does that mean they really know their customer? With a wide range…

CONTINUE

10 Apr
2017

Posted by
Shauna Leighton

How to Create Your Own Integrated Delivery System for Greater Efficiency

Optimize Performance with an Integrated Strategy In an evolving healthcare landscape, guaranteeing quality and compliant content can be challenging as there are more and more channels for information sharing. Consider how long a list of these channels might be for a life sciences company—now consider how important it is to maintain every one of those…

CONTINUE

8 Feb
2017

Posted by
Kaitlyn Merola

Patient Lives are Paramount – Avoid These 3 Content Oversights to Mitigate Misinformation

Companies in the life sciences space have a price to pay when caught improperly or illegally promoting a drug or device. Depending on the offense, that price can range anywhere from an FDA-issued warning letter to settlements upwards of tens of millions of dollars. An FDA-issued warning letter can incur costs associated with process overhaul,…

CONTINUE

24 Jan
2017

Posted by
Chris Monaco

Sales Enablement in Life Sciences: An Interview, Part 2

Below is part two of my conversation with Dr. Jeff Dutremble, senior director of enterprise sales for life sciences at Seismic, as we continued to discuss his background in healthcare, the role of sales enablement in life sciences and the internal and external factors currently affecting companies within the space. You can check out Part…

CONTINUE

17 Jan
2017

Posted by
Chris Monaco

Sales Enablement in Life Sciences: An Interview

I recently sat down with Dr. Jeff Dutremble, senior director of enterprise sales for life sciences at Seismic, and took the opportunity to ask him a few questions about his background in healthcare, the role of sales enablement in life sciences and the internal and external factors currently affecting companies within the space. Below is…

CONTINUE

7 Dec
2016

Posted by
Anne Lorenzano

3 Things We Learned at eXl’s Content Marketing for Life Sciences

Last week, eXl hosted the 5th annual Content Marketing for Life Sciences Conference in Philadelphia, PA. Speakers demonstrated how the most successful brands provide value to their customers by speaking to their specific challenges and goals, and not a particular product. This was Seismic’s first year attending the conference, and to say we learned a…

CONTINUE

30 Nov
2016

Posted by
Anne Lorenzano

4 Sessions to Follow at the Content Marketing for Life Sciences Conference

This coming Thursday and Friday, ExL will be hosting the 5th Annual Content Marketing for Life Sciences Conference in Philadelphia, PA and Seismic will be in attendance! The event’s program explores best practices for content development within the highly regulated life sciences industry, identifies various content marketing distribution channels and demonstrates how to develop timely,…

CONTINUE

15 Nov
2016

Posted by
Anne Lorenzano

10 Tweets from FDA’s Public Hearing on Off-Label Promotion

Last week, the FDA held a 2-day public hearing on “Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products.” The meeting addressed the longstanding disagreement between the FDA and medical product manufacturers regarding the communication of off-label information. The dispute stems from the fact that physicians are allowed to prescribe a medicine or…

CONTINUE